Evidence map›Paper›PMID 29263724›Full record

ArticleClinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases

Efficacy of teriparatide

Paolo Tranquilli Leali, Massimo Balsano, Gianluca Maestretti, Matteo Brusoni, Veronica Amorese, Emanuele Ciurlia, Matteo Andreozzi, Gianfilippo Caggiari, Carlo Doria

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Osteogenesis imperfecta: pathogenesis, classification, and treatment.Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology · 2025
    Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. [Osteogenesis imperfecta : A multidisciplinary challenge].Orthopadie (Heidelberg, Germany) · 2022
    Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Paolo Tranquilli LealiOrthopaedic Department, University of Sassari, Sassari, Italy.
Massimo BalsanoOrthopaedic Department, Santorso Hospital, Santorso (VI), Italy.
Gianluca MaestrettiSpinal Unit, Cantonal Hospital Fribourg, Switzerland.
Matteo BrusoniOrthopaedic Department, University of Sassari, Sassari, Italy.
Veronica AmoreseOrthopaedic Department, University of Sassari, Sassari, Italy.
Emanuele CiurliaOrthopaedic Department, University of Sassari, Sassari, Italy.
Matteo AndreozziOrthopaedic Department, University of Sassari, Sassari, Italy.
Gianfilippo CaggiariOrthopaedic Department, University of Sassari, Sassari, Italy.
Carlo DoriaOrthopaedic Department, University of Sassari, Sassari, Italy.
University of Sassari · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteogenesis imperfecta (OI) is an hereditary disease characterized by low bone mass, increased bone fragility, short stature, and skeletal deformities, few treatment options are currently available. Neridronate is an amino-bisphosphonate, licensed in Italy for the treatment of OI and Paget's disease of bone. A characteristic property of neridronate is that it can be administered both intravenously and intramuscularly, providing an useful system for administration in homecare. Neridronate appears to increase Bone Mineral Density (BMD) in adults with OI and reduces bone resorption by inhibition of osteoclastic activity. Teriparatide (recombinant 1-34 N terminal sequence of human parathyroid hormone) is the first anabolic agent approved for the treatment of patients with osteoporosis and has been reported to increase bone formation by stimulating osteoblast differentiation, osteoblast function, and survival. The results of this study showed a promising role of teriparatide in the therapy of OI type I.

Indexed as

fragility fractureneridronateosteogenesis imperfectateriparatidetherapy

Identifiers

PMID29263724
PMCPMC5726200
OpenAlexW2774972285

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.